Clinical practice guideline for psoriasis management in Latin America.

Authors

Fernando Valenzuela, Juan Raúl Castro Ayarza, Débora Kaplan, Angela María Londoño-García, Karla Del Rocío Macías García, Gabriel Magariños, Enrique Salvador Rivas Záldivar, Manuel Franco, Sara Cano, Carolina Cortés, Paola Jimena Cárdenas, Carla Castro, Renata Ferreira, Susan Martínez, Linda Ibatá Bernal, Julieth Carolina Castillo, Jorge Ospina

Published in

Anais brasileiros de dermatologia. Volume 101. Issue 5. Pages 501449. Aug 29, 2026. Epub Aug 29, 2026.

Abstract

Psoriasis care in Latin America is heterogeneous, and access to systemic agents, biologics, phototherapy, and monitoring resources varies widely across countries.
To develop a regional, evidence-based clinical practice guideline for psoriasis management using GRADE methodology.
The Latin American Psoriasis Society (SOLAPSO) convened a guideline development group, an extended expert panel, patients, and an independent methodological team. We framed clinical questions using PICO, conducted systematic literature reviews, rated certainty of evidence with GRADE, and formulated recommendations through structured Evidence-to-Decision deliberations incorporating benefits and harms, patient values, feasibility, equity, and resource use. Independent external reviewers assessed clarity and methodological quality.
The guideline provides measurable therapeutic targets for plaque psoriasis and key phenotypes, including nail psoriasis, generalized pustular psoriasis, and other special forms. It recommends first-line conventional systemic options (methotrexate, cyclosporine, acitretin) and phototherapy, and it defines indications for escalation to biologic agents or small molecules after inadequate response, intolerance, or contraindications to conventional therapy. It addresses selection across biologic classes, use of biosimilars, and strategies for primary and secondary therapeutic failure. Additional recommendations cover high-impact areas (scalp, nails, palmoplantar, inverse, genital) and special situations (pregnancy, cancer, chronic viral infections, HIV, latent tuberculosis, pediatric psoriasis), plus nonpharmacologic interventions (weight reduction and structured psychological support).
Limitations include heterogeneity in the availability of regional evidence, indirect evidence for some special populations, and variability in access to therapies across Latin American health systems.
This guideline offers an actionable framework for comprehensive psoriasis care in Latin America, balancing best available evidence with regional constraints to support equitable, patient-centered implementation in routine clinical practice.

PMID:
42667799
Bibliographic data and abstract were imported from PubMed on 30 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.